MetaVia (NASDAQ:MTVA) Stock Price Down 4.6% – Here’s What Happened

MetaVia Inc. (NASDAQ:MTVA)’s stock price dropped 4.6% during trading on Thursday . The company traded as low as $0.98 and last traded at $0.98. Approximately 124,033 shares changed hands during trading, a decline of 98% from the average daily volume of 5,063,391 shares. The stock had previously closed at $1.03.

Analyst Upgrades and Downgrades

Separately, HC Wainwright initiated coverage on shares of MetaVia in a research report on Thursday, September 4th. They set a “buy” rating and a $12.00 target price on the stock. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $7.50.

MetaVia Stock Down 4.6%

The company’s 50 day simple moving average is $0.76 and its two-hundred day simple moving average is $0.85.

MetaVia (NASDAQ:MTVA) last announced its earnings results on Thursday, August 7th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.06. Equities research analysts anticipate that MetaVia Inc. will post -3.9 EPS for the current year.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.